John Lechleiter News
Most Popular John Lechleiter Story
Lilly hunkers down for lean years with salary freeze
Eli Lilly ($LLY), languishing in the doldrums of its long-expected "Years YZ," has frozen the salaries of many of its staffers, including those of top management. As Pharmalot reports, the company Read more...
Latest Headlines
- February 6, 2012
- January 10, 2012
- January 5, 2012
- September 21, 2011
- September 2, 2011
- July 8, 2011
- June 23, 2011
- April 27, 2011
- March 9, 2011
- February 7, 2011
- November 10, 2010
- October 22, 2010
- October 1, 2010
- September 10, 2010
- July 7, 2010
- July 6, 2010
- June 11, 2010
- June 4, 2010
- March 31, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
